This trial is active, not recruiting.

Conditions endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer
Treatments carboplatin, docetaxel
Phase phase 2
Sponsor Herbert Irving Comprehensive Cancer Center
Start date May 1998
Trial size 40 participants
Trial identifier NCT00003560, CDR0000066624, CPMC-IRB-8437, NCI-V98-1467


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and carboplatin in treating patients who have stage III or stage IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Masking open label
Primary purpose treatment

Eligibility Criteria

Female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed previously untreated ovarian cancer, fallopian tube carcinoma, papillary serous cancer of the uterus, or primary peritoneal carcinoma - Suboptimally debulked stage III or suboptimally or optimally debulked stage IV - Measurable or evaluable disease - CNS lesions, lytic bone lesions, and radiated lesions (unless there is documented progression after radiotherapy) are not considered measurable - CA 125 levels above 49 units/mL in the absence of cirrhosis or nonmalignant gross ascites are considered evaluable - Ineligible for other high-priority national or institutional study PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - ECOG 0-1 Life expectancy: - More than 2 months Hematopoietic: - WBC greater than 3,000/mm3 - Platelet count greater than 100,000/mm3 Hepatic: - Bilirubin less than 1.5 times upper limit of normal (ULN) - SGOT and/or SGPT less than 2.5 times ULN OR - SGOT and/or SGPT no greater than 2.5 times ULN if alkaline phosphatase no greater than ULN OR - Alkaline phosphatase no greater than 4 times ULN if SGOT and/or SGPT no greater than ULN - No SGOT and/or SGPT greater than 1.5 times ULN with alkaline phosphatase greater than 2.5 times ULN - Alkaline phosphatase less than 350 U/L Renal: - BUN less than 1.5 times normal - Creatinine less than 1.5 times ULN Other: - No other malignancy within the past 5 years except curatively treated carcinoma in situ of the cervix or skin cancer - No other serious medical or psychiatric illness - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior chemotherapy - No other concurrent chemotherapy Endocrine therapy: - No concurrent hormone therapy Radiotherapy: - See Disease Characteristics - No prior radiotherapy Surgery: - See Disease Characteristics

Additional Information

Official title A Phase II Study of Docetaxel and Carboplatin for Suboptimally Debulked Stage III or Stage IV Ovarian and Fallopian Tube Carcinoma
Description OBJECTIVES: - Evaluate the response rate, duration of response, and progression-free and overall survival of previously untreated patients with suboptimally debulked stage III or stage IV ovarian carcinoma, fallopian tube carcinoma, papillary serous cancer of the uterus, or primary peritoneal carcinoma treated with docetaxel and carboplatin. - Evaluate the feasibility and toxicity of this regimen in these patients. - Evaluate the effect of this regimen on quality of life of these patients. OUTLINE: This is an open-label study. Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed prior to therapy and then after every 3 courses of chemotherapy. PROJECTED ACCRUAL: Approximately 14-40 patients will be accrued for this study within 2.5 years.
Trial information was received from ClinicalTrials.gov and was last updated in January 2014.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).